Abstract 447P
Background
Hypomagnesaemia is a well-known side-effect in patients receiving cisplatin-containing chemotherapy. However, a small number of patients, who are receiving weekly cisplatin along with radiotherapy, will show symptoms. Till date in Bangladesh no study has been done to find out the incidence of hypomagnesaemia in concurrent chemo-radiotherapy patients.
Methods
This observational study was done between January, 2018 and February, 2019 at the Cancer Care Center of United Hospital Limited, Dhaka, Bangladesh. A total of 100 non-metastatic lung cancer patients were included in this study. Inclusion criteria were: patients treated with concurrent chemo-radiotherapy and weekly cisplatin; no prior chemotherapy; no prior kidney diseases; ECOG PS 1-2. All patients were treated with 40mg/m2 cisplatin weekly with radiotherapy. Radiotherapy doses were range in 60Gy to 70Gy in 2Gy per fraction. During chemotherapy 1000cc 0.9%NaCl saline was used as pre-hydration and post-hydration. Magnesium level was checked at week 1, week 3 and week 6. Events were categorized according common terminology criteria for adverse events v.4.0. In very severe cases IV magnesium was used, and in mild to moderate cases oral supplement has been used.
Results
Among 100 patients, 63 patients suffered various degrees of hypomagnesaemia. 23 patients were symptomatic for hypomagnesaemia and needed IV correction. And 27 patients were suffering from mild hypomagnesaemia. It has been observed that elderly patients suffer more; 41 patients were above the age of 60 years.
Conclusions
Although hypomagnesaemia is rarely symptomatic, it should be kept in mind that severe grade of hypomagnesaemia can cause fatal damage especially in elderly patients. As, Bangladesh is a developing country and accordingly to their food habits, people have low amounts of dietary magnesium as usual. This finding drives us, to change our daily practice to add IV magnesium (2.5mg/5ml) during post-hydration along with 20mmol potassium n weekly cisplatin chemotherapy to prevent hypomagnesaemia. This was a practice changing finding in our canter. To validate this observational finding we need large prospective multicenter data.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
504P - A single center report for safety and efficacy of CT-707 in Chinese patients with advanced, anaplastic lymphoma kinase-rearranged non-small cell lung cancer or other tumours
Presenter: Peng Song
Session: Poster display session
Resources:
Abstract
519P - Initial results of lung cancer genomic screening project for individualized medicine in Asia: LC-SCRUM-Asia
Presenter: Chih-Hsi Kuo
Session: Poster display session
Resources:
Abstract
521P - A randomized, phase II study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401)
Presenter: Keisuke Baba
Session: Poster display session
Resources:
Abstract
526P - A phase II study of apatinib in patients with recurrent/metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Li Chu
Session: Poster display session
Resources:
Abstract
499P - Prevalence of uncommon epidermal growth factor receptor (EGFR) alterations detected by circulating tumour DNA (ctDNA) in non-small cell lung cancer (NSCLC) patients in Hong Kong
Presenter: Oscar Siu Hong Chan
Session: Poster display session
Resources:
Abstract
489P - Overall survival in patients with EGFRm+ NSCLC receiving sequential afatinib and osimertinib: Updated analysis of the GioTag study
Presenter: Maximilian J. Hochmair
Session: Poster display session
Resources:
Abstract
509P - Second-line treatment after first-line vinorelbine in advanced platinum unfit NSCLC patients: An exploratory analysis of randomized Tempo-Lung trial
Presenter: Andrea Camerini
Session: Poster display session
Resources:
Abstract
500P - Clinico-molecular characteristics of Chinese primary non-small cell lung cancer patients with compound EGFR mutations
Presenter: Jianchun Duan
Session: Poster display session
Resources:
Abstract
527P - A multicenter study of NRG1 fusions in Chinese non-small cell lung cancer patients and response to afatinib using next generation sequencing
Presenter: Xingliang Li
Session: Poster display session
Resources:
Abstract
481P - Updated survival outcomes of the phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small cell lung cancer (KTORG1402)
Presenter: Toshihide Yokoyama
Session: Poster display session
Resources:
Abstract